Xspray Pharma Past Earnings Performance
Past criteria checks 0/6
Xspray Pharma's earnings have been declining at an average annual rate of -42.7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 56.5% per year.
Key information
-42.7%
Earnings growth rate
-33.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -56.5% |
| Return on equity | -24.9% |
| Net Margin | n/a |
| Next Earnings Update | 17 Feb 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Xspray Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -128 | 90 | 38 |
| 30 Jun 22 | 0 | -114 | 76 | 38 |
| 31 Mar 22 | 0 | -102 | 63 | 39 |
| 31 Dec 21 | 0 | -97 | 58 | 39 |
| 30 Sep 21 | 0 | -60 | 53 | 7 |
| 30 Jun 21 | 0 | -57 | 51 | 7 |
| 31 Mar 21 | 0 | -56 | 51 | 7 |
| 31 Dec 20 | 0 | -52 | 47 | 7 |
| 30 Sep 20 | 0 | -56 | 51 | 6 |
| 30 Jun 20 | 0 | -55 | 49 | 6 |
| 31 Mar 20 | 0 | -49 | 44 | 5 |
| 31 Dec 19 | 0 | -46 | 42 | 3 |
| 30 Sep 19 | -22 | -41 | 25 | 11 |
| 30 Jun 19 | -14 | -34 | 22 | 9 |
| 31 Mar 19 | -6 | -30 | 20 | 7 |
| 31 Dec 18 | 0 | -23 | 17 | 6 |
| 30 Sep 18 | 31 | -17 | 23 | 0 |
| 30 Jun 18 | 28 | -16 | 22 | 0 |
| 31 Mar 18 | 29 | -8 | 19 | 0 |
| 31 Dec 17 | 0 | -14 | 11 | 4 |
| 30 Sep 17 | 35 | 1 | 15 | 0 |
| 30 Jun 17 | 30 | -3 | 14 | 0 |
| 31 Mar 17 | 21 | -7 | 12 | 0 |
| 31 Dec 16 | 21 | -4 | 11 | 0 |
Quality Earnings: 6XP is currently unprofitable.
Growing Profit Margin: 6XP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6XP is unprofitable, and losses have increased over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare 6XP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6XP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 6XP has a negative Return on Equity (-24.89%), as it is currently unprofitable.